Relafen Alternatives Compared
| Relafen (nabumetone) | Humira (adalimumab) | Cimzia (certolizumab) |
|
|---|
| Relafen (nabumetone) | Humira (adalimumab) | Cimzia (certolizumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Osteoarthritis, Rheumatoid Arthritis. Relafen may also be used for purposes not listed in this medication guide. |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Prescribed for Ankylosing Spondylitis, Crohn's Disease, Crohn's Disease - Active, Crohn's Disease - Maintenance, Non-Radiographic Axial Spondyloarthritis, Plaque Psoriasis, Polyarticular Juvenile... View more |
Related suggestions Rheumatoid Arthritis
|
|||||||
| More about Relafen (nabumetone) | More about Humira (adalimumab) | More about Cimzia (certolizumab) | ||||||||
| Ratings & Reviews | ||||||||||
|
Relafen has an average rating of 6.8 out of 10 from a total of 38 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 18% reported a negative effect. |
Humira has an average rating of 6.3 out of 10 from a total of 687 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 32% reported a negative effect. |
Cimzia has an average rating of 6.7 out of 10 from a total of 90 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 21% reported a negative effect. |
||||||||
| Drug Class | ||||||||||
| Side Effects | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Humira prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms Available | ||||||||||
|
|
|
||||||||
| Brand Names | ||||||||||
| Other nabumetone brands include: Relafen DS | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more |
N/A |
||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
|
24 hours |
480 hours |
336 hours |
||||||||
| CSA Schedule ** View glossary of terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 384 drugs are known to interact with Relafen:
|
A total of 540 drugs are known to interact with Humira:
|
A total of 427 drugs are known to interact with Cimzia:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
December 24, 1991 |
December 31, 2002 |
April 22, 2008 |
||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.